Glenmark Pharmaceuticals Limited
NSE: GLENMARKMarket Closed • NSE
Day range
52 week range
Glenmark Pharmaceuticals Limited closed at INR2226.70 (-1.06%) on volume 1.09x its 20-day average, trading 12.25% below its 52-week high.
2026-Q2
Q2 FY2026 Financial Results
PAT moved +60.2% QoQ
2026-08-31
DIVIDEND Announced
Dividend - Rs 2.50 Per Share
2025-10-03
DIVIDEND Announced
Interim Dividend - Rs 2.50 Per Share
Revenue and PAT bars use independent scales to make their year-on-year direction readable.
Complete reported financial history · Values use the company's reporting currency
Hover over the chart for exact reported values. Percentage lines use the right-hand axis.
A 0–100 quantitative summary of reported fundamentals. Use the underlying financials and risks for context; the score is not a buy or sell recommendation.
Strengths
Low Debt Profile: Debt-to-Equity is comfortable at 0.06x
High Cash Flow Conversion: CFO/PAT averaged 1.09x over last 3 years
Risks
Subject to cyclical raw material and macro industry pressures
Bull case
Market Leadership: Established operational scale in Drug Manufacturers - Specialty & Generic.
Bear case
Macro Headwinds: Fluctuations in interest rates and sector-specific policy shifts could compress multiples.
Flip condition
Sustained quarterly EBITDA margin expansion above 20% would trigger an upgrade.
Complete dividend, bonus, split, rights and other action history
| Record date | Corporate action | Information | Announcement date | Ex-date |
|---|---|---|---|---|
| 31 Aug 2026 | Dividend | ₹2.50 / share | — | 31 Aug 2026 |
| 03 Oct 2025 | Dividend | ₹2.50 / share | — | 03 Oct 2025 |
| 15 Sept 2025 | Dividend | ₹2.50 / share | — | 15 Sept 2025 |
| — | Dividend | ₹2.50 / share | — | 13 Sept 2024 |
| — | Dividend | ₹2.50 / share | — | 18 Sept 2023 |
| — | Dividend | ₹2.50 / share | — | 12 Sept 2022 |
| — | Dividend | ₹2.50 / share | — | 08 Sept 2021 |
| — | Dividend | ₹2.50 / share | — | 17 Sept 2020 |
| — | Dividend | ₹2.00 / share | — | 19 Sept 2019 |
| — | Dividend | ₹2.00 / share | — | 19 Sept 2018 |
| — | Dividend | ₹2.00 / share | — | 20 Sept 2017 |
| — | Dividend | ₹2.00 / share | — | 03 Aug 2016 |
| — | Dividend | ₹2.00 / share | — | 10 Sept 2015 |
Traded volume and delivery percentage across the latest 20 sessions
Compare valuation, latest quarterly performance and year-on-year growth
| Company name | Market cap ₹ Cr | P/E ratio | Dividend yield % | Quarterly sales ₹ Cr | Profit after tax ₹ Cr | Sales growth % | Profit growth % |
|---|---|---|---|---|---|---|---|
 Sun Pharmaceutical Industries LimitedSUNPHARMA Open analysis | ₹4.22L | 34.90 | 0.91% | ₹15,300.00 | ₹2,901.00 | +10.46% | +26.52% |
 Divi's Laboratories LimitedDIVISLAB Open analysis | ₹2.43L | 82.97 | 0.33% | ₹3,080.00 | ₹902.00 | +27.80% | +65.50% |
 Torrent Pharmaceuticals LimitedTORNTPHARM Open analysis | ₹1.73L | 72.83 | 0.83% | ₹4,128.00 | ₹389.00 | +41.90% | -21.89% |
 Apollo Hospitals Enterprise LimitedAPOLLOHOSP Open analysis | ₹1.13L | 54.32 | 0.25% | ₹7,044.00 | ₹610.00 | +20.58% | +38.32% |
 Zydus Lifesciences LimitedZYDUSLIFE Open analysis | ₹1.12L | 25.03 | 0.09% | ₹8,017.00 | ₹990.00 | +21.95% | -34.91% |
 LENSKART SOLUTIONS LTDLENSKART Open analysis | ₹1.12L | 174.73 | 0.00% | ₹2,714.00 | ₹228.00 | +43.29% | +273.77% |
 Laurus Labs LimitedLAURUSLABS Open analysis | ₹1.11L | 101.83 | 0.12% | ₹2,026.31 | ₹367.60 | +29.10% | +125.49% |
 Cipla LimitedCIPLA Open analysis | ₹1.07L | 31.78 | 0.98% | ₹7,119.00 | ₹786.00 | +2.33% | -39.16% |
Glenmark Pharmaceuticals Limited, together with its subsidiaries, develops, manufactures, and sells generics, specialty medicines, and over the counter (OTC) pharmaceutical products in India, North America, Europe, and internationally. The company provides branded, OTC, and generic formulations in the therapeutic areas of dermatology, respiratory, oncology, immunology, pain management, hypertension, central nervous system, cardiology, diabetes, contraceptives, gynecology, gastroenterology, and anti-infective in the dosage forms of complex injectables and biologics, oral solids, liquids, topical products, and respiratory-metered dose inhaler, dry powder inhaler, and nasal sprays. Its product pipeline includes ISB 2001, a CD38 x BCMA x CD3 TREAT trispecific T cell engager, which is in Phase 1 clinical trial for indication of relapsed/refractory multiple myeloma; ISB 2301, a NK cell engager that is in preclinical trial for solid tumors; and GRC 65327, a Cbl-b inhibitor small molecule for solid tumors. The company's pipeline also comprises ISB 880, an IL-1RAP antagonist monoclonal antibody, which is in Phase 1 clinical trial for the treatment of hidradenitis suppurativa; and ISB 830-X8, a telazorlimab OX40 antagonist antibody that is in Phase 2 clinical trial for the treatment of atopic dermatitis. In addition, the company offers Ryaltris nasal spray for the treatment of seasonal allergic rhinitis. The company was incorporated in 1977 and is based in Mumbai, India.
IndiaHealthcare
Is Glenmark Pharmaceuticals Limited Shariah compliant?
Glenmark Pharmaceuticals Limited is currently screened as Shariah Compliant under AAOIFI Shariah Standard No. 21. Business activities align with Shariah permissible sectors. Debt to Market Cap (0.94%) complies with AAOIFI threshold (≤ 33%).
What is Glenmark Pharmaceuticals Limited's current valuation relative to peers?
Glenmark Pharmaceuticals Limited trades at a P/E of 35.0x compared to the sector median of 37x, and a Price-to-Book of 6.0x.
Is the company financially healthy?
The company has a Debt-to-Equity ratio of 0.06x. Interest coverage is 19.2x.
What are the historical revenue and profit growth rates?
Over the past 5 years, revenue compounded at 7.5% while net profit growth averaged consistent levels.
Market data is informational and may be delayed. Shariah screening follows the displayed methodology. This is not investment advice.
Market data may be delayed. Quote date: 2026-10-16. Financial figures relate to their stated reporting periods. This information is for research and is not a recommendation to buy or sell.